The Recall Desk
HighFDA (Drugs)·D-0348-2023·Announced 2023-03-01

Warfarin Sodium Tablets Recalled Due to Failed Impurity and Degradation Specifications

Rising Pharmaceuticals is recalling Warfarin Sodium Tablets USP 1 mg due to failed impurities and degradation specifications. Approximately 12,216 bottles may have been distributed nationwide.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: FDA Class II pharmaceutical recall triggered by failure to meet product quality specifications for impurities and degradation. No illnesses or injuries are reported in the source material, making this a quality/specification failure without evidence of harm.

Plain-English summary

Rising Pharmaceuticals is recalling Warfarin Sodium Tablets, USP 1 mg (NDC# 57237-119-01) distributed by Rising Health, LLC, Saddle Brook, NJ. The recall affects approximately 12,216 bottles (100-count each) from batch NB101596, with an expiration date of April 30, 2023. The product was distributed to 16 distributors and 8 wholesalers, which may have further distributed it nationwide.

The tablets are being recalled because they failed specifications for impurities and degradation.

Patients who have received this medication should contact their pharmacy or healthcare provider to determine if their supply was affected.

The recalled product

Product
Warfarin Sodium Tablets, USP 1 mg, 100-count bottle, Rx Only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC# 57237-119-01
Manufacturer
RISING PHARMACEUTICALS
Hazard
  • drug-impurity
  • product-degradation

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Batch #: NB101596
  • Exp. 04/30/2023

Distribution

Distributed nationwide across the United States.